SBIA
ATYR

Sheaff Brock Investment Advisors’s aTyr Pharma ATYR Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,000
Closed -$100K – 594
2021
Q3 		$100K Buy
+11,000
New +$65.8K 0.01% 531

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Sheaff Brock Investment Advisors's ATYR Position: Q4 2021 in Review

Sheaff Brock Investment Advisors sold out of aTyr Pharma (ATYR) in Q4 2021, closing a stake of 11,000 shares — an estimated $100K sold.

Sheaff Brock Investment Advisors first reported a position in ATYR in Q3 2021 and held it in 1 quarter. The position peaked at $100K in Q3 2021. 47 funds tracked by Wall St. Rank hold ATYR as of Q4 2021.

  • Sheaff Brock Investment Advisors reported no remaining aTyr Pharma position as of Q4 2021 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 11,000 aTyr Pharma shares in Q4 2021, an estimated $100K.
  • Sheaff Brock Investment Advisors first reported a position in aTyr Pharma in Q3 2021 and held it in 1 quarter.
  • Sheaff Brock Investment Advisors's aTyr Pharma position peaked at $100K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2021.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.